BIO-key International (BKYI) Q4 2025 earnings summary

Executive summary

• 2025 revenue declined 12% year-over-year to $6.1 million, mainly due to timing of a major contract renewal and a strategic shift in EMEA sales focus.

• Hardware and service revenues grew in 2025, offsetting some of the decline in software license revenue.

• Strategic focus on regulated industries, especially defense, banking, healthcare, and government, is driving growth opportunities, with notable wins in Europe, Middle East, and Asia.

• Ended 2025 with $2.7 million in cash and a book value of $7.6 million, up from $3.8 million in 2024.

• Significant product innovation and new partnerships are expected to support future growth.

Financial highlights

• 2025 total revenue: $6.1 million, down from $6.9 million in 2024 (12% decrease).

• Hardware revenue more than doubled to $1.3 million; service revenue up 6% to $1.2 million.

• Gross margin was 77.5% in 2025, down from 81.4% in 2024, due to revenue mix.

• Net loss increased to $4.6 million ($0.69/share) from $4.3 million ($2.09/share) in 2024.

• Operating expenses reduced by 7%; SG&A down 11%.

Outlook and guidance

• Q1 2026 revenue expected at $2.2 million, up 37% year-over-year.

• Targeting breakeven and profitability in early 2026, supported by top-line growth, expanding customer deployments, and expense management.

• Anticipates continued strong gross margins (80%+), with stable R&D expenses.

• ARR remains in the $6–7 million range, with a focus on multi-year subscription deals.

• Anticipates quarterly financial fluctuations due to timing of large orders.